Advertisement

Biological Approach in the Treatment of Crohn’s Disease

  • Luca Frulloni
  • Laura Bernardoni
  • Chiara Scattolini
  • Italo Vantini

Keywords

Inflammatory Bowel Disease Certolizumab Pegol Infliximab Therapy Antitumor Necrosis Factor Antitumor Necrosis Factor Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hanauer SB (2006) Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 12(Suppl 1):S3–S9PubMedCrossRefGoogle Scholar
  2. 2.
    Gustot T, Lemmers A, Louis E et al (2005) Profile of soluble cytokine receptors in Crohn’s disease. Gut 54:488–495PubMedCrossRefGoogle Scholar
  3. 3.
    Lindsay JO, Hodgson HJ (2001) Review article: the immunoregulatory cytokine interleukin-10 — a therapy for Crohn’s disease? Aliment Pharmacol Ther 15:1709–1716PubMedCrossRefGoogle Scholar
  4. 4.
    Sandborn WJ, Targan SR (2002) Biologic therapy of inflammatory bowel disease. Gastroenterology 122:1592–1608PubMedCrossRefGoogle Scholar
  5. 5.
    Vermeire S, Rutgeerts P (2004) Novel biological strategies in inflammatory bowel diseases. Inflamm Bowel Dis 10:s44–s51PubMedCrossRefGoogle Scholar
  6. 6.
    Papadakis KA, Targan S (2000) Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 119:1148–1157PubMedCrossRefGoogle Scholar
  7. 7.
    van den Brande J, Hommes DW, Peppelenbosch MP (2005) Infliximab induced T lymphocyte apoptosis in Crohn’s disease. J Rheumatol 74(Suppl):26–30Google Scholar
  8. 8.
    Sandborn WJ, Hanauer SB (1999) Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 5:119–133PubMedCrossRefGoogle Scholar
  9. 9.
    Ringheanu M, Daum F, Markowitz J et al (2004) Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn’s disease. Inflamm Bowel Dis 10:801–810PubMedCrossRefGoogle Scholar
  10. 10.
    D’Haens G, Van Deventer S, Van Hogezand R et al (1999) Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology 116:1029–1034PubMedCrossRefGoogle Scholar
  11. 11.
    Geboes K, Rutgeerts P, Opdenakker G et al (2005) Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment of Crohn’s diseas. Curr Med Res Opin 21:1741–1754PubMedCrossRefGoogle Scholar
  12. 12.
    Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359:1541–1549PubMedCrossRefGoogle Scholar
  13. 13.
    Sandborn WJ, Hanauer SB (2002) Infliximab in the treatment of Crohn’s disease: a user’s guide for clinicians. Am J Gastroenterol 97:2962–2972PubMedCrossRefGoogle Scholar
  14. 14.
    Rutgeerts PJ (2001) Review article: the limitations of corticosteroid therapy in Crohn’s disease. Aliment Pharmacol Ther 15:1515–1525PubMedCrossRefGoogle Scholar
  15. 15.
    Laine L, Hanauer SB (2003) Considerations in the management of steroid-dependent Crohn’s disease. Gastroenterology 125:906–910PubMedCrossRefGoogle Scholar
  16. 16.
    Hanauer SB (2003) Crohn’s disease: step up or top down therapy. Best Pract Res Clin Gastroenterol 17:131–137PubMedCrossRefGoogle Scholar
  17. 17.
    Targan SR, Hanauer SB, van Deventer SJ et al (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA 2 Study Group. N Engl J Med 337:1029–1035PubMedCrossRefGoogle Scholar
  18. 18.
    van Dullemen HM, van Deventer SJ, Hommes DW et al (1995) Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109:129–135PubMedCrossRefGoogle Scholar
  19. 19.
    Baert FJ, D’Haens GR, Peeters M et al (1999) Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology 116:22–28PubMedCrossRefGoogle Scholar
  20. 20.
    Present DH, Rutgeerts P, Targan S et al (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340:1398–1405PubMedCrossRefGoogle Scholar
  21. 21.
    Rutgeerts P, D’Haens G, Targan S et al (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 117:761–769PubMedCrossRefGoogle Scholar
  22. 22.
    Farrell RJ, Shah SA, Lodhavia PJ et al (2000) Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gastroenterol 95:3490–3497PubMedCrossRefGoogle Scholar
  23. 23.
    Cohen RD (2001) Efficacy and safety of repeated infliximab infusions for Crohn’s disease: 1-year clinical experience. Inflamm Bowel Dis 7(Suppl 1):S17–S22PubMedGoogle Scholar
  24. 24.
    Arnott ID, McDonald D, Williams A, Ghosh S (2001) Clinical use of Infliximab in Crohn’s disease: the Edinburgh experience. Aliment Pharmacol Ther 15:1639–1646PubMedCrossRefGoogle Scholar
  25. 25.
    Hommes DW, van de Heisteeg BH, van der Spek M, et al (2002) Infliximab treatment for Crohn’s disease: one-year experience in a Dutch academic hospital. Inflamm Bowel Dis 8:81–86PubMedCrossRefGoogle Scholar
  26. 26.
    Ardizzone S, Colombo E, Maconi G et al (2002) Infliximab in treatment of Crohn’s disease: the Milan experience. Dig Liver Dis 34:411–418PubMedCrossRefGoogle Scholar
  27. 27.
    Arslan S, Kav T, Besisik F et al (2003) Clinical outcome of Crohn’s disease treated with infliximab. Hepatogastroenterology 50:952–956PubMedGoogle Scholar
  28. 28.
    Sands BE, Anderson FH, Bernstein CN et al (2004) Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 350:876–885PubMedCrossRefGoogle Scholar
  29. 29.
    Wenzl HH, Reinisch W, Jahnel J et al (2004) Austrian infliximab experience in Crohn’s disease: a nationwide cooperative study with long-term follow-up. Eur J Gastroenterol Hepatol 16:767–773PubMedCrossRefGoogle Scholar
  30. 30.
    Orlando A, Colombo E, Kohn A et al (2005) Infliximab in the treatment of Crohn’s disease: predictors of response in an Italian multicentric open study. Dig Liver Dis 37:577–583PubMedCrossRefGoogle Scholar
  31. 31.
    Centocor, Inc. (2002) Remicade (infliximab) for i.v. injection. Volume Package insert. Melvern, PAGoogle Scholar
  32. 32.
    Rutgeerts P, Mayer L, Schreiber S (2001) Infliximab (Remicade) maintenance treatment strategy is superior to episodic treatment in patients with Crohn’s disease. Am J Gastroenterol 96:S302–S303CrossRefGoogle Scholar
  33. 33.
    Menachem Y, Avidan B, Lavy A et al (2005) Increasing the infliximab dose is beneficial in Crohn’s disease patients who responded to a lower dose and relapsed. Digestion 72:124–128PubMedCrossRefGoogle Scholar
  34. 34.
    Allan A, Keighley RB (1988) Management of perianal disease. World J Surg 12:198–202PubMedCrossRefGoogle Scholar
  35. 35.
    Regueiro M, Mardini H (2003) Treatment of perianal fistulizing Crohn’s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 9:98–103PubMedCrossRefGoogle Scholar
  36. 36.
    Present DH (2003) Crohn’s fistula: current concepts in management. Gastroenterology 124:1629–1635PubMedCrossRefGoogle Scholar
  37. 37.
    Felley C, Mottet C, Juillerat P et al (2005) Fistulizing Crohn’s disease. Digestion 71:26–28PubMedCrossRefGoogle Scholar
  38. 38.
    Schroder O, Blumenstein I, Schulte-Bockholt A, Stein J (2004) Combining infliximab and methotrexate in fistulizing Crohn’s disease resistant or intolerant to azathioprine. Aliment Pharmacol Ther 19:295–301PubMedCrossRefGoogle Scholar
  39. 39.
    Talbot C, Sagar PM, Johnston MJ et al (2005) Infliximab in the surgical management of complex fistulating anal Crohn’s disease. Colorectal Dis 7:164–168PubMedCrossRefGoogle Scholar
  40. 40.
    Poggioli G, Laureati S, Pierangeli F et al (2005) Local injection of infliximab for the tratment of perianal Crohn’s disease. Dis Colon Rectum 48:768–774PubMedCrossRefGoogle Scholar
  41. 41.
    Parsi MA, Lashner BA, Achkar JP et al (2004) Type of fistula determines response to infliximab in patients with fistulous Crohn’s disease. Am J Gastroenterol 99:445–449PubMedCrossRefGoogle Scholar
  42. 42.
    Wheeler C, Marion JF, Present DH (1998) Medical therapy, not surgery, is the appropriate first line treatement of Crohn’s enterovesical fistula. Gastroenterology 114A:1113CrossRefGoogle Scholar
  43. 43.
    Sonoda T, Haull T, Piedmonte MR, Fazzi M (2002) Outcomes of primary repair of anorectal and rectovaginal fistulas using the endorectal advancement flap. Dis Colon Rectum 45:1622–1628PubMedCrossRefGoogle Scholar
  44. 44.
    Sorrentino D, Avellini C, Beltrami CA et al (2005) Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn’s disease. Int J Colorectal Dis [Epub ahead of print]Google Scholar
  45. 45.
    Parsi MA, Achkar JP, Richardson S et al (2002) Predictors of response to infliximab in patients with Crohn’s disease. Gastroenterology 123:707–713PubMedCrossRefGoogle Scholar
  46. 46.
    Arnott ID, McNeill G, Satsangi J (2003) An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn’s disease. Aliment Pharmacol Ther 17:1451–1457PubMedCrossRefGoogle Scholar
  47. 47.
    Holtmann MH, Neurath MF (2005) Anti-TNF strategies in stenosing and fistulizing Crohn’s disease. Int J Colorectal Dis 20:1–8PubMedCrossRefGoogle Scholar
  48. 48.
    Biancone L, Tosti C, Fina D et al (2003) Review article: maintenance treatment of Crohn’s disease. Aliment Pharmacol Ther 17(Suppl 2):31–37PubMedCrossRefGoogle Scholar
  49. 49.
    Boirivant M, Leoni M, Tariciotti D et al (1988) The clinical significance of serum C reactive protein levels in Crohn’s disease. Results of a prospective longitudinal study. J Clin Gastroenterol 10:401–405PubMedCrossRefGoogle Scholar
  50. 50.
    Ollendorf DA, Massarotti E, Birbara C, Burgess SM (2005) Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm 11:383–393PubMedGoogle Scholar
  51. 51.
    Lichtenstein GR, Yan S, Bala M et al (2005) Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology 128:862–869PubMedCrossRefGoogle Scholar
  52. 52.
    Bodger K (2005) Economic implications of biological therapies for Crohn’s disease: review of infliximab. Pharmacoeconomics 23:875–888PubMedCrossRefGoogle Scholar
  53. 53.
    Cadahia V, Garcia-Carbonero A, Vivas S et al (2004) Infliximab improves quality of life in the short-term in patients with fistulizing Crohn’s disease in clinical practice. Rev Esp Enferm Dig 96:369–374; 374–378PubMedCrossRefGoogle Scholar
  54. 54.
    Clark W, Raftery J, Song F et al (2003) Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn’s disease. Health Technol Assess 7:1–67PubMedGoogle Scholar
  55. 55.
    Wicks AC, Thomas C, Curran R, Mayberry JF (2002) Infliximab and Crohn’s QOL. Aliment Pharmacol Ther 16:1831–1832PubMedCrossRefGoogle Scholar
  56. 56.
    Hommes DW, van Deventer SJ (2003) Infliximab therapy in Crohn’s disease: safety issues. Neth J Med 61:100–104PubMedGoogle Scholar
  57. 57.
    Colombel JF, Loftus EV Jr, Tremaine WJ et al (2004) The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology 126:19–31PubMedCrossRefGoogle Scholar
  58. 58.
    Hanauer SB (1999) Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther 13(Suppl 4):16–22; discussion 38PubMedCrossRefGoogle Scholar
  59. 59.
    Cheifetz A, Smedley M, Martin S et al (2003) The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 98:1315–1324PubMedCrossRefGoogle Scholar
  60. 60.
    Farrell RJ, Alsahli M, Jeen YT et al (2003) Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology 124:917–924PubMedCrossRefGoogle Scholar
  61. 61.
    Sandborn WJ (2003) Preventing antibodies to infliximab in patients with Crohn’s disease: optimize not immunize. Gastroenterology 124:1140–1145PubMedGoogle Scholar
  62. 62.
    Baert F, Noman M, Vermeire S et al (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 348:601–608PubMedCrossRefGoogle Scholar
  63. 63.
    Hanauer SB, Wagner CL, Bala M et al (2004) Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol 2:542–553PubMedCrossRefGoogle Scholar
  64. 64.
    Rutgeerts P, Van Assche G, Vermeire S (2004) Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126:1593–1610PubMedCrossRefGoogle Scholar
  65. 65.
    Han PD, Cohen RD (2004) Managing immunogenic responses to infliximab: treatment implications for patients with Crohn’s disease. Drugs 64:1767–1777PubMedCrossRefGoogle Scholar
  66. 66.
    Crandall WV, Mackner LM (2003) Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 17:75–84PubMedCrossRefGoogle Scholar
  67. 67.
    Gardam MA, Keystone EC, Menzies R et al (2003) Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3:148–155PubMedCrossRefGoogle Scholar
  68. 68.
    Beenhouwer D, Wallis R, Broder M, Furst DE (2004) Mechanisms of action of tumor necrosis factor antagonist and granulomatous infections. J Rheumatol 31:1888–1892PubMedGoogle Scholar
  69. 69.
    Wallis RS, Broder M, Wong J et al (2005) Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 41(Suppl 3):S194–S198PubMedCrossRefGoogle Scholar
  70. 70.
    Wallis RS, Broder MS, Wong JY et al (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38:1261–1265PubMedCrossRefGoogle Scholar
  71. 71.
    Velayos FS, Sandborn WJ (2004) Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn’s disease. Inflamm Bowel Dis 10:657–660PubMedCrossRefGoogle Scholar
  72. 72.
    Keane J, Gershon S, Wise RP, Mirabile-Levens E et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098–1104PubMedCrossRefGoogle Scholar
  73. 73.
    Warris A, Bjorneklett A, Gaustad P (2001) Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 344:1099–1100PubMedCrossRefGoogle Scholar
  74. 74.
    Hamilton CD (2004) Infectious complications of treatment with biologic agents. Curr Opin Rheumatol 16:393–398PubMedCrossRefGoogle Scholar
  75. 75.
    Listing J, Strangfeld A, Kary S et al (2005) Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52:3403–3412PubMedCrossRefGoogle Scholar
  76. 76.
    Ormerod LP (2004) Tuberculosis and anti-TNF-alpha treatment. Thorax 59:921PubMedCrossRefGoogle Scholar
  77. 77.
    De Rosa FG, Bonora S, Di Perri G (2002) Tuberculosis and treatment with infliximab. N Engl J Med 346:623–626PubMedCrossRefGoogle Scholar
  78. 78.
    Zhang Z, Correa H, Begue RE (2002) Tuberculosis and treatment with infliximab. N Engl J Med 346:623–626PubMedCrossRefGoogle Scholar
  79. 79.
    Morelli J, Wilson FA (2000) Does administration of infliximab increase susceptibility to listeriosis? Am J Gastroenterol 95:841–842PubMedCrossRefGoogle Scholar
  80. 80.
    Tai TL, O’Rourke KP, McWeeney M et al (2002) Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology (Oxford) 41:951–952PubMedCrossRefGoogle Scholar
  81. 81.
    Seddik M, Meliez H, Seguy D et al (2004) Pneumocystis jiroveci (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn’s disease. Inflamm Bowel Dis 10:436–437PubMedCrossRefGoogle Scholar
  82. 82.
    Kaur N, Mahl TC (2004) Pneumocystis carinii pneumonia with oral candidiasis after infliximab therapy for Crohn’s disease. Dig Dis Sci 49:1458–1460PubMedCrossRefGoogle Scholar
  83. 83.
    Seddik M, Melliez H, Seguy D et al (2005) Pneumocystis jiroveci (carinii) pneumonia after initiation of infliximab and azathioprine therapy in a patient with Crohn’s disease. Inflamm Bowel Dis 11:618–620PubMedCrossRefGoogle Scholar
  84. 84.
    Wood KL, Hage CA, Knox KS et al (2003) Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med 167:1279–1282PubMedCrossRefGoogle Scholar
  85. 85.
    Lee JH, Slifman NR, Gershon SK et al (2002) Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 46:2565–2570PubMedCrossRefGoogle Scholar
  86. 86.
    Nakelchik M, Mangino JE (2002) Reactivation of histoplasmosis after treatment with infliximab. Am J Med 112:78PubMedCrossRefGoogle Scholar
  87. 87.
    Bowie VL, Snella KA, Gopalachar AS, Bharadwaj P (2004) Listeria meningitis associated with infliximab. Ann Pharmacother 38:58–61PubMedCrossRefGoogle Scholar
  88. 88.
    Aparicio AG, Munoz-Fernandez S, Bonilla G et al (2003) Report of an additional case of anti-tumor necrosis factor therapy and Listeria monocytogenes infection: comment on the letter by Gluck et al. Arthritis Rheum 48:1764–1765; author reply 1765–1766PubMedCrossRefGoogle Scholar
  89. 89.
    Slifman NR, Gershon SK, Lee JH et al (2003) Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 48:319–324PubMedCrossRefGoogle Scholar
  90. 90.
    Kamath BM, Mamula P, Baldassano RN, Markowitz JE (2002) Listeria meningitis after treatment with infliximab. J Pediatr Gastroenterol Nutr 34:410–412PubMedCrossRefGoogle Scholar
  91. 91.
    Gluck T, Linde HJ, Scholmerich J et al (2002) Antitumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum 46:2255–2257; author reply 2257PubMedCrossRefGoogle Scholar
  92. 92.
    Alderson JW, Van Dinter TG Jr et al (2005) Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn’s disease and chronic hepatitis C: a case study and review of the literature. MedGenMed 7:7PubMedGoogle Scholar
  93. 93.
    van der Klooster JM, Bosman RJ, Oudemans-van Straaten HM et al (2003) Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med 29:2327–2329PubMedCrossRefGoogle Scholar
  94. 94.
    De Rosa FG, Shaz D, Campagna AC et al (2003) Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case? Infect Control Hosp Epidemiol 24:477–482PubMedCrossRefGoogle Scholar
  95. 95.
    Marinos G, Naoumov NV, Rossol S et al (1995) Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroenterology 108:1453–1463PubMedCrossRefGoogle Scholar
  96. 96.
    Tilg H (1997) New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 112:1017–1021PubMedCrossRefGoogle Scholar
  97. 97.
    del Valle Garcia-Sanchez M, Gomez-Camacho F et al (2004) Infliximab therapy in a patient with Crohn’s disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 10:701–702PubMedCrossRefGoogle Scholar
  98. 98.
    Campbell S, Ghosh S (2001) Infliximab therapy for Crohn’s disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 13:191–192PubMedCrossRefGoogle Scholar
  99. 99.
    Peterson JR, Hsu FC, Simkin PA, Wener MH (2003) Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 62:1078–1082PubMedCrossRefGoogle Scholar
  100. 100.
    Biancone L, Pavia M, Del Vecchio Blanco G et al (2001) Hepatitis B and C virus infection in Crohn’s disease. Inflamm Bowel Dis 7:287–294PubMedCrossRefGoogle Scholar
  101. 101.
    Holtmann MH, Galle PR, Neurath MF (2003) Treatment of patients with Crohn’s disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. Am J Gastroenterol 98:504–505PubMedCrossRefGoogle Scholar
  102. 102.
    Biancone L, Del Vecchio Blanco G et al (2002) Immunomodulatory drugs in Crohn’s disease patients with hepatitis B or C virus infection. Gastroenterology 122:593–594PubMedGoogle Scholar
  103. 103.
    Wendling D, Auge B, Bettinger D et al (2005) Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 64:788–789PubMedCrossRefGoogle Scholar
  104. 104.
    Ueno Y, Tanaka S, Shimamoto M et al (2005) Infliximab therapy for Crohn’s disease in a patient with chronic hepatitis B. Dig Dis Sci 50:163–166PubMedCrossRefGoogle Scholar
  105. 105.
    Esteve M, Saro C, Gonzalez-Huix F et al (2004) Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut 53:1363–1365PubMedCrossRefGoogle Scholar
  106. 106.
    Ostuni P, Botsios C, Punzi L et al (2003) Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 62:686–687PubMedCrossRefGoogle Scholar
  107. 107.
    Michel M, Duvoux C, Hezode C, Cherqui D (2003) Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still’s disease. J Rheumatol 30:1624–1625PubMedGoogle Scholar
  108. 108.
    Sandborn WJ, Loftus EV (2004) Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut 53:780–782PubMedCrossRefGoogle Scholar
  109. 109.
    Biancone L, Orlando A, Kohn A et al (2006) Infliximab and newly diagnosed neoplasia in Crohn’s disease: a multicentre matched pair study. Gut 55:228–233PubMedCrossRefGoogle Scholar
  110. 110.
    Kandiel A, Fraser AG, Korelitz BI et al (2005) Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54:1121–1125PubMedCrossRefGoogle Scholar
  111. 111.
    Tan CW, Wilson GE, Howat JM, Shreeve DR (2001) Rectal lymphoma in ulcerative colitis treated with azathioprine. Eur J Gastroenterol Hepatol 13:989–992PubMedCrossRefGoogle Scholar
  112. 112.
    Lewis JD, Schwartz JS, Lichtenstein GR (2000) Azathioprine for maintenance of remission in Crohn’s disease: benefits outweigh the risk of lymphoma. Gastroenterology 118:1018–1024PubMedCrossRefGoogle Scholar
  113. 113.
    Phillips T, Salisbury J, Leigh I, Baker H (1987) Non-Hodgkin’s lymphoma associated with long-term azathioprine therapy. Clin Exp Dermatol 12:444–445PubMedCrossRefGoogle Scholar
  114. 114.
    McGovern DP, Jewell DP (2005) Risks and benefits of azathioprine therapy. Gut 54:1055–1059PubMedCrossRefGoogle Scholar
  115. 115.
    Connell WR, Kamm MA, Dickson M et al (1994) Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 343:1249–1252PubMedCrossRefGoogle Scholar
  116. 116.
    Behnam SM, Behnam SE, Koo JY (2005) TNF-alpha inhibitors and congestive heart failure. Skinmed 4:363–368PubMedGoogle Scholar
  117. 117.
    Gupta S, Tripathi CD (2005) Current status of TNF blocking therapy in heart failure. Indian J Med Sci 59:363–366PubMedCrossRefGoogle Scholar
  118. 118.
    Levine B, Kalman J, Mayer L et al (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323:236–241PubMedCrossRefGoogle Scholar
  119. 119.
    Rauchhaus M, Doehner W, Francis DP et al (2000) Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102:3060–3067PubMedGoogle Scholar
  120. 120.
    Torre-Amione G, Vooletich MT, Farmer JA (2000) Role of tumour necrosis factor-alpha in the progression of heart failure: therapeutic implications. Drugs 59:745–751PubMedCrossRefGoogle Scholar
  121. 121.
    Torre-Amione G, Kapadia S, Benedict C et al (1996) Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27:1201–1206PubMedCrossRefGoogle Scholar
  122. 122.
    Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT (2003). Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107:3133–140PubMedCrossRefGoogle Scholar
  123. 123.
    Khanna D, McMahon M, Furst DE (2004) Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here? Arthritis Rheum 50:1040–1050PubMedCrossRefGoogle Scholar
  124. 124.
    Tanno M, Nakamura I, Kobayashi S et al (2005) New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients. Clin Rheumatol 23:1–5Google Scholar
  125. 125.
    Freeman HJ, Flak B (2005) Demyelination-like syndrome in Crohn’s disease after infliximab therapy. Can J Gastroenterol 19:313–316PubMedGoogle Scholar
  126. 126.
    Enayati PJ, Papadakis KA (2005). Association of antitumor necrosis factor therapy with the development of multiple sclerosis. J Clin Gastroenterol 39:303–306PubMedCrossRefGoogle Scholar
  127. 127.
    Thomas CW Jr, Weinshenker BG, Sandborn WJ (2004) Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn’s disease. Inflamm Bowel Dis 10:28–31PubMedCrossRefGoogle Scholar
  128. 128.
    Gupta G, Gelfand JM, Lewis JD (2005) Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 129:819–826PubMedCrossRefGoogle Scholar
  129. 129.
    Katz JA (2004) Pregnancy and inflammatory bowel disease. Curr Opin Gastroenterol 20:328–332PubMedCrossRefGoogle Scholar
  130. 130.
    Froehlich F, Juillerat P, Felley C et al (2005) Treatment of postoperative Crohn’s disease. Digestion 71:49–53PubMedCrossRefGoogle Scholar
  131. 131.
    Rutgeerts P (2001) Strategies in the prevention of postoperative recurrence in Crohn’s disease. Best Pract Res Clin Gastroenterol 17:63–73CrossRefGoogle Scholar
  132. 132.
    Rutgeerts P, Geboes K, Vantrappen G et al (1990) Predictability of the postoperative course of Crohn’s disease. Gastroenterology 99:956–963PubMedGoogle Scholar
  133. 133.
    Rutgeerts P (1994) Recurrence of Crohn’s disease in the neoterminal ileum after ileal resection: is prevention therapy possible? Neth J Med 45:60–64PubMedGoogle Scholar
  134. 134.
    Olaison G, Smedh K, Sjodahl R (1992) Natural course of Crohn’s disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 33:331–335PubMedGoogle Scholar
  135. 135.
    Becker JM (1999) Surgical therapy for ulcerative colitis and Crohn’s disease. Gastroenterol Clin North Am 28:371–90, viii-ixPubMedCrossRefGoogle Scholar
  136. 136.
    Rutgeerts P, Van Assche G, Vermeire S et al (2005) Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 128:856–861PubMedCrossRefGoogle Scholar
  137. 137.
    Rutgeerts P, Hiele M, Geboes K et al (1995) Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 108:1617–1621PubMedCrossRefGoogle Scholar
  138. 138.
    Hanauer S, Sandborn W, Rutgeerts P et al (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSICI trial. Gastroenterology 130:323–333PubMedCrossRefGoogle Scholar
  139. 139.
    Papadakis KA, Shaye OA, Vasiliauskas EA et al (2005) Safety and efficacy of adalimumab (D2E7) in Crohn’s disease patients with an attenuated response to infliximab. Am J Gastroenterol 100:75–79PubMedCrossRefGoogle Scholar
  140. 140.
    Hanauer SB (2004) Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: overview of randomized clinical studies. Rev Gastroenterol Disord 4(Suppl 3):S18–S24PubMedGoogle Scholar
  141. 141.
    Youdim A, Vasiliauskas EA, Targan SR et al (2004) A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 10:333–338PubMedCrossRefGoogle Scholar
  142. 142.
    Sandborn WJ, Hanauer S, Loftus EV Jr et al (2004) An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am J Gastroenterol 99:1984–1989PubMedCrossRefGoogle Scholar
  143. 143.
    Stallmach A, Giese T, Schmidt C (2004) Severe anaphylactic reaction to infliximab: successful treatment with adalimumab — report of a case. Eur J Gastroenterol Hepatol 16:627–630PubMedCrossRefGoogle Scholar
  144. 144.
    D’Haens G, Swijsen C, Noman M et al (2001) Etanercept in the treatment of active refractory Crohn’s disease: a single-center pilot trial. Am J Gastroenterol 96:2564–2568PubMedCrossRefGoogle Scholar
  145. 145.
    Sandborn WJ, Hanauer SB, Katz S et al (2001) Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121:1088–1094PubMedCrossRefGoogle Scholar
  146. 146.
    Van den Brande JM, Braat H, van den Brink GR et al (2003) Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology 124:1774–1785PubMedCrossRefGoogle Scholar
  147. 147.
    Rutgeerts P, Lemmens L, Van Assche G et al (2003) Treatment of active Crohn’s disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 17:185–192PubMedCrossRefGoogle Scholar
  148. 148.
    Stack WA, Mann SD, Roy AJ et al (1997) Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn’s disease. Lancet 349:521–524PubMedCrossRefGoogle Scholar
  149. 149.
    Sandborn WJ, Feagan BG, Hanauer SB et al (2001) An engineered human antibody to TNF (CDP571) for active Crohn’s disease: a randomized double-blind placebo-controlled trial. Gastroenterology 120:1330–1338PubMedCrossRefGoogle Scholar
  150. 150.
    Feagan BG, Sandborn WJ, Baker JP et al (2005) A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn’s disease. Aliment Pharmacol Ther 21:373–384PubMedCrossRefGoogle Scholar
  151. 151.
    Sandborn WJ, Feagan BG, Radford-Smith G et al (2004) CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial. Gut 53:1485–1493PubMedCrossRefGoogle Scholar
  152. 152.
    Schreiber S, Rutgeerts P, Fedorak RN et al (2005) A randomized, placebo-controlled trial of Certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology 129:807–818PubMedCrossRefGoogle Scholar
  153. 153.
    Bauditz J, Wedel S, Lochs H (2002) Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn’s disease. Gut 50:196–200PubMedCrossRefGoogle Scholar
  154. 154.
    Vasiliauskas EA, Kam LY, Abreu-Martin MT et al (1999) An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn’s disease. Gastroenterology 117:1278–1287PubMedCrossRefGoogle Scholar
  155. 155.
    Ehrenpreis ED, Kane SV, Cohen LB et al (1999) Thalidomide therapy for patients with refractory Crohn’s disease: an open-label trial. Gastroenterology 117:1271–1277PubMedCrossRefGoogle Scholar
  156. 156.
    Bariol C, Meagher AP, Vickers CR et al (2002) Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol 17:135–139PubMedCrossRefGoogle Scholar
  157. 157.
    Sabate JM, Villarejo J, Lemann M et al (2002) An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn’s disease. Aliment Pharmacol Ther 16:1117–1124PubMedCrossRefGoogle Scholar
  158. 158.
    Tilg H, van Montfrans C, van den Ende A et al (2002) Treatment of Crohn’s disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut 50:191–195PubMedCrossRefGoogle Scholar
  159. 159.
    Fedorak RN, Gangl A, Elson CO et al (2000) Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn’s disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 119:1473–1482PubMedCrossRefGoogle Scholar
  160. 160.
    Schreiber S, Fedorak RN, Nielsen OH et al (2000) Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn’s disease. Crohn’s Disease IL-10 Cooperative Study Group. Gastroenterology 119:1461–1472PubMedCrossRefGoogle Scholar
  161. 161.
    van Deventer SJ, Elson CO, Fedorak RN (1997) Multiple doses of intravenous interleukin 10 in steroidrefractory Crohn’s disease. Crohn’s Disease Study Group. Gastroenterology 113:383–389PubMedCrossRefGoogle Scholar
  162. 162.
    Colombel JF, Rutgeerts P, Malchow H et al (2001) Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn’s disease. Gut 49:42–46PubMedCrossRefGoogle Scholar
  163. 163.
    Lindsay JO, Ciesielski CJ, Scheinin T et al (2003) Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis. Gut 52:363–369PubMedCrossRefGoogle Scholar
  164. 164.
    Sands BE, Bank S, Sninsky CA et al (1999) Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn’s disease. Gastroenterology 117:58–64PubMedCrossRefGoogle Scholar
  165. 165.
    Sands BE, Winston BD, Salzberg B et al (2002) Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn’s disease. Aliment Pharmacol Ther 16:399–406PubMedCrossRefGoogle Scholar
  166. 166.
    Sandborn WJ, Yednock TA (2003) Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am J Gastroenterol 98:2372–2382PubMedCrossRefGoogle Scholar
  167. 167.
    Ghosh S, Goldin E, Gordon FH et al (2003) Natalizumab for active Crohn’s disease. N Engl J Med 348:24–32PubMedCrossRefGoogle Scholar
  168. 168.
    Sandborn WJ, Colombel JF, Enns R et al (2005) Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 353:1912–1925PubMedCrossRefGoogle Scholar
  169. 169.
    Gordon FH, Lai CW, Hamilton MI et al (2001) A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn’s disease. Gastroenterology 121:268–274PubMedCrossRefGoogle Scholar
  170. 170.
    Berger T, Deisenhammer F (2005) Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis. N Engl J Med 353:1744–1746; author reply 1744–1746PubMedCrossRefGoogle Scholar
  171. 171.
    Langer-Gould A, Atlas SW, Green AJ et al (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353:375–381PubMedCrossRefGoogle Scholar
  172. 172.
    Van Assche G, Van Ranst M, Sciot R et al (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 353:362–368PubMedCrossRefGoogle Scholar
  173. 173.
    Berger JR, Koralnik IJ (2005) Progressive multifocal leukoencephalopathy and natalizumab—unforeseen consequences. N Engl J Med 353:414–416PubMedCrossRefGoogle Scholar
  174. 174.
    Sandborn WJ (1997) Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn’s disease. Am J Gastroenterol 92:876–879PubMedGoogle Scholar
  175. 175.
    Ierardi E, Principi M, Francavilla R et al (2001) Oral tacrolimus long-term therapy in patients with Crohn’s disease and steroid resistance. Aliment Pharmacol Ther 15:371–377PubMedCrossRefGoogle Scholar
  176. 176.
    Sandborn WJ, Present DH, Isaacs KL et al (2003) Tacrolimus for the treatment of fistulas in patients with Crohn’s disease: a randomized, placebo-controlled trial. Gastroenterology 125:380–388PubMedCrossRefGoogle Scholar
  177. 177.
    Gonzalez-Lama Y, Abreu L, Vera MI et al (2005) Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn’s disease: a pilot study. Inflamm Bowel Dis 11:8–15PubMedCrossRefGoogle Scholar
  178. 178.
    Fukuda A, Nakase H, Seno H et al (2005) Refractory enterovesical and duodenocolic fistulas in Crohn’s disease successfully managed with tacrolimus. J Gastroenterol 40:433–435PubMedCrossRefGoogle Scholar
  179. 179.
    Miehsler W, Reinisch W, Moser G et al (2001) Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn’s disease? Am J Gastroenterol 96:782–787PubMedCrossRefGoogle Scholar
  180. 180.
    Neurath MF, Wanitschke R, Peters M et al (1999) Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn’s disease. Gut 44:625–628PubMedCrossRefGoogle Scholar
  181. 181.
    Ford AC, Towler RJ, Moayyedi P et al (2003) Mycophenolate mofetil in refractory inflammatory bowel disease. Aliment Pharmacol Ther 17:1365–1369PubMedCrossRefGoogle Scholar
  182. 182.
    Fickert P, Hinterleitner TA, Wenzl HH et al (1998) Mycophenolate mofetil in patients with Crohn’s disease. Am J Gastroenterol; 93:2529–2532PubMedCrossRefGoogle Scholar
  183. 183.
    Fellermann K, Steffen M, Stein J et al (2000) Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther 14:171–176PubMedCrossRefGoogle Scholar
  184. 184.
    Wenzl HH, Hinterleitner TA, Aichbichler BW et al (2004) Mycophenolate mofetil for Crohn’s disease: short-term efficacy and long-term outcome. Aliment Pharmacol Ther 19:427–434PubMedCrossRefGoogle Scholar
  185. 185.
    Moreels TG, Pelckmans PA (2005) Gastrointestinal parasites: potential therapy for refractory inflammatory bowel diseases. Inflamm Bowel Dis 11:178–184PubMedCrossRefGoogle Scholar
  186. 186.
    Elliott DE, Li J, Blum A et al (2003) Exposure to schistosome eggs protects mice from TNBS-induced colitis. Am J Physiol Gastrointest Liver Physiol 284:G385–391PubMedGoogle Scholar
  187. 187.
    Moreels TG, Nieuwendijk RJ, De Man JG et al (2004) Concurrent infection with Schistosoma mansoni attenuates inflammation induced changes in colonic morphology, cytokine levels, and smooth muscle contractility of trinitrobenzene sulphonic acid induced colitis in rats. Gut 53:99–107PubMedCrossRefGoogle Scholar
  188. 188.
    Khan WI, Blennerhasset PA, Varghese AK et al (2002) Intestinal nematode infection ameliorates experimental colitis in mice. Infect Immun 70:5931–5937PubMedCrossRefGoogle Scholar
  189. 189.
    Summers RW, Elliott DE, Qadir K et al (2003) Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am J Gastroenterol 98:2034–2041PubMedCrossRefGoogle Scholar
  190. 190.
    Summers RW, Elliott DE, Urban JF Jr et al (2005) Trichuris suis therapy in Crohn’s disease. Gut 54:87–90PubMedCrossRefGoogle Scholar
  191. 191.
    Sartor RB (2004) Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126:1620–1633PubMedCrossRefGoogle Scholar
  192. 192.
    Fedorak RN, Madsen KL (2004) Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis 10:286–299PubMedCrossRefGoogle Scholar
  193. 193.
    Egan LJ, Sandborn WJ (2005) Positioning novel biologic, probiotic, and apheresis therapies for Crohn’s disease and ulcerative colitis. Curr Gastroenterol Rep 7:485–491PubMedGoogle Scholar
  194. 194.
    Schultz M, Timmer A, Herfarth HH et al (2004) Lactobacillus GG in inducing and maintaining remission of Crohn’s disease. BMC Gastroenterol 4:5PubMedCrossRefGoogle Scholar
  195. 195.
    Bousvaros A, Guandalini S, Baldassano RN et al (2005) A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease. Inflamm Bowel Dis 11:833–839PubMedCrossRefGoogle Scholar
  196. 196.
    Prantera C, Scribano ML, Falasco G et al (2002) Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomized controlled trial with Lactobacillus GG. Gut 51:405–409PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2006

Authors and Affiliations

  • Luca Frulloni
    • 1
  • Laura Bernardoni
    • 2
  • Chiara Scattolini
    • 1
  • Italo Vantini
    • 3
  1. 1.Department of Gastroenterology Policlinico “G.B. Rossi”University of VeronaVeronaItaly
  2. 2.Unit of Digestive Endoscopy Policlinico “G.B. Rossi”University of VeronaVeronaItaly
  3. 3.Department of Biomedical and Surgical Sciences Division of GastroenterologyPoliclinico “G.B. Rossi”VeronaItaly

Personalised recommendations